Similar articles for PMID: 16291735

Year	Number of Results
1993	1
1997	1
1998	12
1999	3
2000	5
2001	10
2002	14
2003	19
2004	28
2005	18
2006	16
2007	18
2008	16
2009	14
2010	14
2011	10
2012	17
2013	15
2014	26
2015	34
2016	27
2017	22
2018	12
2019	11
2020	16
2021	14
2022	10
2023	4
2024	0

1

Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection.

Hazra R, Gafni RI, Maldarelli F, Balis FM, Tullio AN, DeCarlo E, Worrell CJ, Steinberg SM, Flaherty J, Yale K, Kearney BP, Zeichner SL. Hazra R, et al. Pediatrics. 2005 Dec;116(6):e846-54. doi: 10.1542/peds.2005-0975. Epub 2005 Nov 15. Pediatrics. 2005. PMID: 16291735 Clinical Trial.

2

Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children.

Gafni RI, Hazra R, Reynolds JC, Maldarelli F, Tullio AN, DeCarlo E, Worrell CJ, Flaherty JF, Yale K, Kearney BP, Zeichner SL. Gafni RI, et al. Pediatrics. 2006 Sep;118(3):e711-8. doi: 10.1542/peds.2005-2525. Epub 2006 Aug 21. Pediatrics. 2006. PMID: 16923923 Clinical Trial.

3

Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects.

Gallant JE, Rodriguez AE, Weinberg WG, Young B, Berger DS, Lim ML, Liao Q, Ross L, Johnson J, Shaefer MS; ESS30009 Study. Gallant JE, et al. J Infect Dis. 2005 Dec 1;192(11):1921-30. doi: 10.1086/498069. Epub 2005 Oct 25. J Infect Dis. 2005. PMID: 16267763 Clinical Trial.

4

Long-term efficacy and safety of tenofovir disoproxil fumarate in HIV-1-infected adolescents failing antiretroviral therapy: the final results of study GS-US-104-0321.

Della Negra M, De Carvalho AP, De Aquino MZ, Pinto JA, Da Silva MT, Andreatta KN, Graham B, Liu YP, Quirk EK. Della Negra M, et al. Pediatr Infect Dis J. 2015 Apr;34(4):398-405. doi: 10.1097/INF.0000000000000649. Pediatr Infect Dis J. 2015. PMID: 25599284 Clinical Trial.

5

Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial.

Squires K, Pozniak AL, Pierone G Jr, Steinhart CR, Berger D, Bellos NC, Becker SL, Wulfsohn M, Miller MD, Toole JJ, Coakley DF, Cheng A; Study 907 Team. Squires K, et al. Ann Intern Med. 2003 Sep 2;139(5 Pt 1):313-20. doi: 10.7326/0003-4819-139-5_part_1-200309020-00006. Ann Intern Med. 2003. PMID: 12965939 Clinical Trial.

6

Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.

Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, Coakley DF, Lu B, Toole JJ, Cheng AK; 903 Study Group. Gallant JE, et al. JAMA. 2004 Jul 14;292(2):191-201. doi: 10.1001/jama.292.2.191. JAMA. 2004. PMID: 15249568 Clinical Trial.

7

A randomized trial of two-drug versus three-drug tenofovir-containing maintenance regimens in virologically controlled HIV-1 patients.

Girard PM, Cabié A, Michelet C, Verdon R, Katlama C, Mercié P, Morand-Joubert L, Pétour P, Monchecourt F, Chêne G, Trylesinski A; COOL Study Team. Girard PM, et al. J Antimicrob Chemother. 2009 Jul;64(1):126-34. doi: 10.1093/jac/dkp141. Epub 2009 Apr 29. J Antimicrob Chemother. 2009. PMID: 19403652 Clinical Trial.

8

Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.

Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, Campo RE, Lu B, McColl D, Chuck S, Enejosa J, Toole JJ, Cheng AK; Study 934 Group. Gallant JE, et al. N Engl J Med. 2006 Jan 19;354(3):251-60. doi: 10.1056/NEJMoa051871. N Engl J Med. 2006. PMID: 16421366 Free article. Clinical Trial.

9

Evaluation of four tenofovir-containing regimens as first-line treatments in Cameroon and Senegal: the ANRS 12115 DAYANA Trial.

Landman R, Koulla-Shiro S, Sow PS, Ngolle M, Diallo MB, Guèye NF, Le Moing V, Eymard-Duvernay S, Benalycherif A, Charpentier C, Peytavin G, Delaporte E, Girard PM; DAYANA Study Group. Landman R, et al. Antivir Ther. 2014;19(1):51-9. doi: 10.3851/IMP2675. Epub 2013 Aug 23. Antivir Ther. 2014. PMID: 23970206 Clinical Trial.

10

Efficacy, safety and pharmacokinetics of tenofovir disoproxil fumarate in virologic-suppressed HIV-infected children using weight-band dosing.

Aurpibul L, Cressey TR, Sricharoenchai S, Wittawatmongkol O, Sirisanthana V, Phongsamart W, Sudjaritruk T, Chokephaibulkit K. Aurpibul L, et al. Pediatr Infect Dis J. 2015 Apr;34(4):392-7. doi: 10.1097/INF.0000000000000633. Pediatr Infect Dis J. 2015. PMID: 25760566

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

382 results

Results by year